CLRM-11 ALK TYROSINE KINASE INHIBITOR THERAPY AND BRAIN METASTASES IN NON-SMALL CELL LUNG CANCER: IMPACT ON TUMOR SIZE AND DISTRIBUTION

Non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase rearrangement (ALK+) is known to have a high propensity to form brain metastases (BrM), with over 50% of ALK+ lung cancer patients developing BrM despite effective ALK tyrosine kinase inhibitor (TKI) therapy with central nervous syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamson, David Olayinka, Cheunkarndee, Tia, Marrone, Kristen, Murray, Joseph, Feliciano, Joy, Hann, Christine, Ettinger, David, Anagnostou, Valsamo, Forde, Patrick, Brahmer, Julie, Levy, Benjamin, Scott, Susan, Lam, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Clinical Research Methods
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402416/
http://dx.doi.org/10.1093/noajnl/vdad070.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402416/
http://dx.doi.org/10.1093/noajnl/vdad070.033

Ejemplares similares